Metin Kurtoglu sold $345k of RNAC
Chief Technology Officer at Cartesian Therapeutics, Inc.. 13,664 shares at an average of $25.26, traded Dec 9, 2024, filed Dec 11, 2024.
Score components
- +15RoleOfficer
- +15Trade size$345k at market
- +5Share of holdings soldSold 22% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001453687-24-000145, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2024 | MOption exercise Common Stock | +10,763 | $1.41 | $15k | 61,796 | Dec 11, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stock | -6,224 | $25.26 | $157k | 55,572 | Dec 11, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stock | -4,539 | $25.83 | $117k | 51,033 | Dec 11, 2024 |
| Dec 10, 2024 | MOption exercise Common Stock | +2,901 | $1.41 | $4,090 | 53,934 | Dec 11, 2024 |
| Dec 10, 2024 | SOpen-market sale Common Stock | -2,901 | $24.35 | $71k | 51,033 | Dec 11, 2024 |
| Dec 9, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -10,763 | - | - | 82,000 | Dec 11, 2024 |
| Dec 10, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -2,901 | - | - | 79,099 | Dec 11, 2024 |
Related signals
Other insiders at Cartesian Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $1.4M 89,863 shares | +1% | |
| 30Weak | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $366k 20,967 shares | +0% | |
| 54Moderate | Cartesian Therapeutics, Inc. | Carsten Brunn President and CEO | $290k 17,271 shares | -8% | |
| 48Moderate | Cartesian Therapeutics, Inc. | Blaine Davis Chief Financial Officer | $134k 7,989 shares | -8% | |
| 40Moderate | Cartesian Therapeutics, Inc. | Emily English Chief Operations Officer | $30k 1,797 shares | -4% | |
| 36Weak | Cartesian Therapeutics, Inc. | Christopher M Jewell Chief Scientific Officer | $43k 2,550 shares | -5% | |
| 35Weak | Cartesian Therapeutics, Inc. | Milos Miljkovic Chief Medical Officer | $32k 1,880 shares | -5% | |
| 39Weak | Cartesian Therapeutics, Inc. | Metin Kurtoglu Chief Technology Officer | $82k 4,875 shares | -7% | |
| 40Moderate | RNACbuy Cartesian Therapeutics, Inc. | Timothy A Springer director, owner | $965k 52,189 shares | +1% | |
| 55Moderate | Cartesian Therapeutics, Inc. | Metin Kurtoglu Chief Technology Officer | $649k 38,689 shares | -76% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.